It has been brought to my attention that when I wrote the August 8, 2013 post on Pharma Sponsored Assistance Programs, I neglected to mention another excellent assistance program for men with advanced prostate cancer. The Chronic Disease Fund (CDF) has two funds that might be of specific interest to men with castrate resistant prostate [...]
Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by [...]
I received an email from a lady from Australia that I though would be informative to share. It discusses genetic links and risk factors for hormonally related (including prostate) cancers: HER EMAIL TO ME Hi there :) I hope you don't mind me emailing you? I'm a lady from Australia and have 3 uncles with [...]
OK, I give up, what’s a man to eat? Red meat and dairy are terrible for us, we all already know that, but now eggs and poultry are on the do not eat list. Pretty much this leaves us with vegetables only. I know, a vegetarian or vegan diet is understood to be best, but [...]
There are a number of funds available to assist men with their treatment co-pays and to help cover travel for treatments. These funds receive their financial support from the drug companies (pharama) which make voluntary contributions. Within the overarching fund there are many disease specific funds that supply co-pay and or travel support for individuals. [...]
Enzalutamide (Xtandi) monotherapy induced striking declines in prostate-specific antigen (PSA) in a majority of patients with hormone-naive prostate cancer in a phase II trial, and this oral agent appears to have little effect on bone mineral density. If these findings are confirmed in a phase III trial, then enzalutamide may be an alternative to androgen [...]
The following post is actually a response to a listserve issue over the side effects of Xofigo. I decided to post my response here to avoid the limit of lines allowed on the listserve and because I feel that it is also of interest to my regular readers of this blog. My response is using [...]
Although there are now many new treatments for advanced prostate cancer, hormone therapy (ADT) has remained the standard of care for the last 70 years. While hormone therapy can provide pain relief, it is never curative. Long-term hormone therapy produces decreased quality of life. Men treated with hormone therapy have weight gain, experience impotence, decreased [...]
Not terribly surprising, but recent research shows that less than one-third of all cancer survivors of adult cancers in the United States ever had conversations with their healthcare providers about their psychosocial needs. The latest study showing this was published in the Journal of Clinical Oncology.1 This study was a large population-based study of 1777 [...]
The US Senate Appropriations Subcommittee on Defense yesterday marked-up their version of the FY14 Defense Appropriations Act. The full committee is scheduled to mark up tomorrow Thursday). The following is an excerpt from the committee’s summary of the bill: Significant increases to DoD medical research efforts, including: o $200 million for the Peer-Reviewed Medical Research [...]
